TOKYO – Japan's Taiho Oncology Inc. won U.S. FDA approval for its oral combination anticancer drug TAS-102 (trifluridine hydrochloride) for refractory metastatic colorectal cancer (mCRC), which is marketed in Japan under the brand name Lonsurf.

TOKYO – Domestic and multinational pharmaceutical companies want Japan to maintain a scheme that adds price premiums to certain drugs, which makes it easier for drug companies to recoup research and development costs.

TOKYO – Domestic and multinational pharmaceutical companies want Japan to maintain a scheme that adds price premiums to certain drugs, which makes it easier for drug companies to recoup research and development costs.

TOKYO – Six months after winning PMDA approval, Eli Lilly Japan and Nippon Boehringer Ingelheim (NBI) recently disclosed plans to launch the first insulin glargine biosimilar in Japan, a market in which biosimilars are advancing, albeit slowly.

TOKYO – Six months after winning PMDA approval, Eli Lilly Japan and Nippon Boehringer Ingelheim (NBI) recently disclosed plans to launch the first insulin glargine biosimilar in Japan, a market in which biosimilars are advancing, albeit slowly.

TOKYO – Hoping to combine the affordability of biosimilars with the promise of combination cancer therapies, London-based Astrazeneca plc is making its first foray into biosimilar development through a joint venture with Fujifilm Kyowa Kirin Biologics Co. Ltd. (FKB).

TOKYO – Hoping to combine the affordability of biosimilars with the promise of combination cancer therapies, London-based Astrazeneca plc is making its first foray into biosimilar development through a joint venture with Fujifilm Kyowa Kirin Biologics Co. Ltd. (FKB).

TOKYO – A new initiative in Japan aims to bring together the research resources of multiple stakeholders, including a handful of multinational biotech companies, to bear on the fight against some insidious neglected diseases.